Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**Sj-p80** is the recombinant ~80 kDa large subunit of the calcium-activated neutral protease (calpain) from *Schistosoma japonicum*, developed as a low-cost transmission-blocking veterinary vaccine antigen for Asiatic schistosomiasis. Produced via prokaryotic expression in *E. coli* with scalable purification processes achieving up to >99% purity at four levels, it is formulated with adjuvants like Montanide ISA61 VG for intramuscular administration. In mouse challenge models, immunization reduced adult worm burden by up to 46.1%, liver egg deposition by 23.4–51.4%, intestinal egg load by 1.9–55.1%, and egg hatching by up to 31.6%, demonstrating prophylactic efficacy and immunogenicity with robust antibody titers.[1][5]
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Sj-p80.